6 March 2017 - Deborah Wilkes
Archived
Perrigo is sharpening its focus on consumer healthcare following pressure from an activist investor. The troubled company has agreed to divest its rights to the royalty stream from Tysabri (natalizumab) – the multiple sclerosis treatment marketed by Biogen – and is reviewing strategic alternatives for its Active Pharmaceutical Ingredients (API) business.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.